Results 11 to 20 of about 6,049 (169)

Febuxostat: a new drug for an old disease. Do we really need it? [PDF]

Italian Journal of Medicine, 2013
BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration.
Giovanni Gulli, Luigi de Filippis
doaj   +2 more sources

Febuxostat methanol solvate

Acta Crystallographica Section E, 2011
In the title compound {systematic name: [2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid (febuxostat) methanol monosolvate}, C16H16N2O3S·CH4O, the benzene and thiazole rings in the febuxostat molecule are twisted at 5.3 ...
Qi-Ying Jiang, Jing-Jing Qian, Jian-Ming Gu, Gu-Ping Tang, Xiu-Rong Hu   +4 more
doaj   +2 more sources

FEBUXOSTAT FOR TREATMENT OF CHRONIC HYPERURICEMIA IN GOUT PATIENTS [PDF]

Медицинский совет, 2017
Febuxostat, a selective  inhibitor of isoforms xantinoxydoreductase, it is an alternative to a limited number of medications to reduce urates levels  applied in recent decades.
M. S. Petrova, V. I. Mazurov, O. V. Inamova   +2 more
doaj   +2 more sources

Efficacy and safety of febuxostat in elderly female patients

Clinical Interventions in Aging, 2014
Tomohiro Mizuno,1,2 Takahiro Hayashi,3 Sayo Hikosaka,1 Yuka Shimabukuro,1 Maho Murase,1 Kazuo Takahashi,2 Hiroki Hayashi,2 Yukio Yuzawa,2 Tadashi Nagamatsu,1 Shigeki Yamada3 1Department of Analytical Pharmacology, Graduate School of Pharmacy, Meijo ...
Mizuno T, Hayashi T, Hikosaka S, Shimabukuro Y, Murase M, Takahashi K, Hayashi H, Yuzawa Y, Nagamatsu T, Yamada S   +9 more
doaj   +1 more source

Febuxostat in the management of hyperuricemia and chronic gout: a review

Therapeutics and Clinical Risk Management, 2008
Miao Hu, Brian TomlinsonDivision of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, ChinaAbstract: Febuxostat is a novel, potent, non ...
Miao Hu, Brian Tomlinson
doaj   +1 more source

Impact of urate-lowering therapy on quality of life indicators in patients with gout

Современная ревматология, 2021
Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ...
M. N. Chikina, O. V. Zhelyabina, M. S. Eliseev   +2 more
doaj   +1 more source

The current treatment strategy for gouty arthritis

Современная ревматология, 2018
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA).
M. S. Petrova, М. M. Musiychuk, V. I. Mazurov   +2 more
doaj   +1 more source

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia.
Honghu Tang, Beibei Cui, Yiyu Chen, Lin Chen, Zhihong Wang, Ning Zhang, Yanlan Yang, Xiaodong Wang, Xiangliang Xie, Lingyun Sun, Wantai Dang, Xianyang Wang, Runzi Li, Jianjun Zou, Yi Zhao, Yi Liu   +15 more
doaj   +1 more source

Evaluation of analgesic activity of allopurinol and febuxostat in experimental analgesic models in mice

Indian Journal of Pain, 2015
Background: Allopurinol and febuxostat are xanthine oxidase inhibitors which are used in the treatment of hyperuricemia and gout. Pain is one of the important symptoms in gout patients.
Promod D Shankpal, J H Hotwani, Kunal A Chitnis, Dnyanesh S Tadke, Vijay R Kokani   +4 more
doaj   +1 more source

Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats

Frontiers in Pharmacology, 2022
Doxorubicin (DOX) is an anticancer agent for treating solid and soft tissue malignancies. However, the clinical use of DOX is restricted by cumulative, dose-dependent cardiotoxicity.
Hayder M. Al-Kuraishy, Hany A. Al-Hussaniy, Ali I. Al-Gareeb, Walaa A. Negm, Aya H. El-Kadem, Gaber El-Saber Batiha, Nermeen N. Welson, Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Ahmed H Qasem, Carlos Adam Conte-Junior   +10 more
doaj   +1 more source